Nyxoah has raised €25 million (nearly $28 million) in its latest fundraising round, with CPAP maker ResMed (NYSE:RMD) joining as a new shareholder. Nyxoah is a Mont-Saint-Guibert, Belgium–based company with a battery-free, leadless and minimally invasive neurostimulator to treat obstructive sleep apnea. It gained a CE Mark for its Genio system last year. Cochlear (ASX:COH) and several […]
Nyxoah
Cochlear joins $17m round for sleep apnea nueromod dev Nyxoah
Cochlear Ltd. (ASX:COH) has joined a $17.1 million (EU €15 million) funding round for Nyxoah to support the development and commercialization of its hypoglossal nerve stim therapy for treating obstructive sleep apnea. Australian hearing tech developer Cochlear lead the round, investing $14.7 million (EU €13 million). The round was also joined by several existing Nyxoah shareholders, […]
Belgian neurostim-based sleep apnea dev Nyxoah raises $20m
Belgian developer Nyxoah said yesterday it raised $20 million (EU €18 million) to support its progress towards eventual CE Mark and FDA approval for its novel neurostimulation based disruptive therapy for patients with obstructive sleep apnea. The company is developing a lead-free neurostimulator designed to deliver bilateral hypoglossal nerve stimulation to treat moderate to severe […]
